{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:37:43Z","timestamp":1790491063739,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Schizophrenia (SCZ) and bipolar disorder (BPD) are associated with abnormal expression of immune-related factors (IRFs), which have been proposed as biomarkers of either disease diagnosis (trait markers) or treatment (state markers). However, the state markers have been found to be less reproducible than the trait markers in previous studies. In the current study, we focused on the changes of IRFs in blood of SCZ and BPD patients receiving monotherapy. SCZ (<jats:italic>N<\/jats:italic>\u2009=\u200949) and BPD (<jats:italic>N<\/jats:italic>\u2009=\u200949) Chinese patients were recruited at acute episode and followed for 9 to 51 days until remission. Blood samples were collected at two state-points, acute state before treatment and remission state after treatment. A total of 41 IRFs in plasma were quantified by the Luminex assay. After adjusting covariates, we found four cytokines or cytokine receptors were significantly increased at remission when compared to acute episode in all the patients, including CD30, BAFF, CCL20, and CXCL10 (Bonferroni corrected<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). CD30 and BAFF were consistently increased in both SCZ and BPD while the increase of CCL20 was only observed in BPD but not SCZ when analyzing the two disorders separately. CXCL10 change was not significant in either SCZ or BPD alone. The changes of these four factors were correlated with each other, but not with clinical features. CD30 concentration in the BPD acute state was correlated with sleep quality (Spearman\u2019s<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub>\u2009=\u20090.365, Bonferroni corrected<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Overall, we found that four factors (CD30, BAFF, CCL20, and CXCL10) might be associated with treatment of psychosis.<\/jats:p>","DOI":"10.1038\/s41398-022-01968-0","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T18:12:07Z","timestamp":1653588727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Changes of immune-related factors in the blood of schizophrenia and bipolar disorder patients receiving monotherapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Fangyuan","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihua","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5114-2282","authenticated-orcid":false,"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-4415","authenticated-orcid":false,"given":"Chunyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"1968_CR1","doi-asserted-by":"publisher","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","volume":"1","author":"RS Kahn","year":"2015","unstructured":"Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat Rev Dis Prim. 2015;1:15067.","journal-title":"Nat Rev Dis Prim"},{"key":"1968_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1906193","volume":"383","author":"AF Carvalho","year":"2020","unstructured":"Carvalho AF, Firth J, Vieta E. Bipolar disorder. N. Engl J Med. 2020;383:58\u201366.","journal-title":"N. Engl J Med"},{"key":"1968_CR3","doi-asserted-by":"crossref","unstructured":"Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, Revicki D. Costs of bipolar disorder. PharmacoEconomics. 2003;21:601\u201322.","DOI":"10.2165\/00019053-200321090-00001"},{"key":"1968_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40273-016-0444-6","volume":"35","author":"H Jin","year":"2017","unstructured":"Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. PharmacoEconomics. 2017;35:25\u201342.","journal-title":"PharmacoEconomics"},{"key":"1968_CR5","unstructured":"Bipolar D. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Electronic address drve, Bipolar D, Schizophrenia Working Group of the Psychiatric Genomics C. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell. 2018;173:1705\u201315."},{"key":"1968_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrneurol.2009.71","volume":"5","author":"JB Potash","year":"2009","unstructured":"Potash JB, Bienvenu OJ. Neuropsychiatric disorders: Shared genetics of bipolar disorder and schizophrenia. Nat Rev Neurol. 2009;5:299\u2013300.","journal-title":"Nat Rev Neurol"},{"key":"1968_CR7","doi-asserted-by":"crossref","unstructured":"Pearlson GD. Etiologic, phenomenologic, and endophenotypic overlap of schizophrenia and bipolar disorder. Annu Rev Clin Psychol. 2015;11:251\u201381.","DOI":"10.1146\/annurev-clinpsy-032814-112915"},{"key":"1968_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/10673220590923164","volume":"13","author":"L Citrome","year":"2005","unstructured":"Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry. 2005;13:28\u201342.","journal-title":"Harv Rev Psychiatry"},{"key":"1968_CR9","doi-asserted-by":"crossref","unstructured":"Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, Zorrilla I, Lopez P, Vieta E, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36:355\u201371.","DOI":"10.1097\/JCP.0000000000000523"},{"key":"1968_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neubiorev.2013.11.006","volume":"38","author":"KA Feigenson","year":"2014","unstructured":"Feigenson KA, Kusnecov AW, Silverstein SM. Inflammation and the two-hit hypothesis of schizophrenia. Neurosci Biobehav Rev. 2014;38:72\u201393.","journal-title":"Neurosci Biobehav Rev"},{"key":"1968_CR11","doi-asserted-by":"crossref","unstructured":"Rosenblat JD, McIntyre RS. Bipolar disorder and inflammation. Psychiatr Clin North Am. 2016;39:125\u201337.","DOI":"10.1016\/j.psc.2015.09.006"},{"key":"1968_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.schres.2017.04.015","volume":"192","author":"B Misiak","year":"2018","unstructured":"Misiak B, Stanczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophr Res. 2018;192:16\u201329.","journal-title":"Schizophr Res"},{"key":"1968_CR13","doi-asserted-by":"crossref","unstructured":"Lizano P, Lutz O, Xu Y, Rubin LH, Paskowitz L, Lee AM, et al. Multivariate relationships between peripheral inflammatory marker subtypes and cognitive and brain structural measures in psychosis. Mol Psychiatry. 2020;26:3430\u201343.","DOI":"10.1038\/s41380-020-00914-0"},{"key":"1968_CR14","doi-asserted-by":"crossref","unstructured":"Lema YY, Gamo NJ, Yang K, Ishizuka K. Trait and state biomarkers for psychiatric disorders: Importance of infrastructure to bridge the gap between basic and clinical research and industry. Psychiatry Clin Neurosci. 2018;72:482\u20139.","DOI":"10.1111\/pcn.12669"},{"key":"1968_CR15","doi-asserted-by":"crossref","unstructured":"Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21:1696\u2013709.","DOI":"10.1038\/mp.2016.3"},{"key":"1968_CR16","doi-asserted-by":"crossref","unstructured":"Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663\u201371.","DOI":"10.1016\/j.biopsych.2011.04.013"},{"key":"1968_CR17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jpsychires.2011.03.002","volume":"45","author":"BS Fernandes","year":"2011","unstructured":"Fernandes BS, Gama CS, Cereser KM, Yatham LN, Fries GR, Colpo G, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45:995\u20131004.","journal-title":"J Psychiatr Res"},{"key":"1968_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0570-y","volume":"9","author":"N Yuan","year":"2019","unstructured":"Yuan N, Chen Y, Xia Y, Dai J, Liu C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Transl Psychiatry. 2019;9:233.","journal-title":"Transl Psychiatry"},{"key":"1968_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0219-2","volume":"8","author":"AL Comes","year":"2018","unstructured":"Comes AL, Papiol S, Mueller T, Geyer PE, Mann M, Schulze TG. Proteomics for blood biomarker exploration of severe mental illness: pitfalls of the past and potential for the future. Transl Psychiatry. 2018;8:160.","journal-title":"Transl Psychiatry"},{"key":"1968_CR20","doi-asserted-by":"crossref","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull. 1987;13:261\u201376.","DOI":"10.1093\/schbul\/13.2.261"},{"key":"1968_CR21","doi-asserted-by":"crossref","unstructured":"Bech P, Bolwig TG, Kramp P, Rafaelsen OJ. The bech-rafaelsen mania scale and the hamilton depression scale. Acta Psychiatr Scandinavica. 1979;59:420\u201330.","DOI":"10.1111\/j.1600-0447.1979.tb04484.x"},{"key":"1968_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol, Neurosurg, Psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol, Neurosurg, Psychiatry"},{"key":"1968_CR23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol). 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B (Methodol)"},{"key":"1968_CR24","doi-asserted-by":"crossref","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149\u201360.","DOI":"10.3758\/BRM.41.4.1149"},{"key":"1968_CR25","doi-asserted-by":"crossref","unstructured":"Dostert C, Grusdat M, Letellier E, Brenner D. The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol Rev. 2019;99:115\u201360.","DOI":"10.1152\/physrev.00045.2017"},{"key":"1968_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.psychres.2014.10.007","volume":"225","author":"Y El Kissi","year":"2015","unstructured":"El Kissi Y, Samoud S, Mtiraoui A, Letaief L, Hannachi N, Ayachi M, et al. Increased Interleukin-17 and decreased BAFF serum levels in drug-free acute schizophrenia. Psychiatry Res. 2015;225:58\u201363.","journal-title":"Psychiatry Res"},{"key":"1968_CR27","doi-asserted-by":"crossref","unstructured":"Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36:705\u201316.","DOI":"10.1016\/j.immuni.2012.05.008"},{"key":"1968_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neubiorev.2014.02.001","volume":"42","author":"MJ Stuart","year":"2014","unstructured":"Stuart MJ, Baune BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev. 2014;42:93\u2013115.","journal-title":"Neurosci Biobehav Rev"},{"key":"1968_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/1568008053174723","volume":"5","author":"E Lazzeri","year":"2005","unstructured":"Lazzeri E, Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune, Endocr Metab Disord. 2005;5:109\u201318.","journal-title":"Curr Drug Targets Immune, Endocr Metab Disord"},{"key":"1968_CR30","doi-asserted-by":"crossref","unstructured":"Lee AYS, Korner H. The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology. Immunobiology. 2019;224:449\u201354.","DOI":"10.1016\/j.imbio.2019.01.005"},{"key":"1968_CR31","doi-asserted-by":"crossref","unstructured":"Forray A, Yonkers KA. The collision of mental health, substance use disorder, and suicide. Obstet Gynecol. 2021;137:1083\u201390.","DOI":"10.1097\/AOG.0000000000004391"},{"key":"1968_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jpsychires.2019.10.008","volume":"120","author":"Y Shinko","year":"2020","unstructured":"Shinko Y, Otsuka I, Okazaki S, Horai T, Boku S, Takahashi M, et al. Chemokine alterations in the postmortem brains of suicide completers. J Psychiatr Res. 2020;120:29\u201333.","journal-title":"J Psychiatr Res"},{"key":"1968_CR33","doi-asserted-by":"crossref","unstructured":"Oyler-Yaniv A, Oyler-Yaniv J, Whitlock BM, Liu Z, Germain RN, Huse M, et al. A tunable diffusion-consumption mechanism of cytokine propagation enables plasticity in cell-to-cell communication in the immune system. Immunity. 2017;46:609\u201320.","DOI":"10.1016\/j.immuni.2017.03.011"},{"key":"1968_CR34","doi-asserted-by":"crossref","unstructured":"Gouwy M, Struyf S, Proost P, Van, Damme J. Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev. 2005;16:561\u201380.","DOI":"10.1016\/j.cytogfr.2005.03.005"},{"key":"1968_CR35","doi-asserted-by":"crossref","unstructured":"Epstein MM, Breen EC, Magpantay L, Detels R, Lepone L, Penugonda S, et al. Temporal stability of serum concentrations of cytokines and soluble receptors measured across two years in low-risk HIV-seronegative men. Cancer Epidemiol Biomark Prev. 2013;22:2009\u201315.","DOI":"10.1158\/1055-9965.EPI-13-0379"},{"key":"1968_CR36","doi-asserted-by":"crossref","unstructured":"Navarro SL, Brasky TM, Schwarz Y, Song X, Wang CY, Kristal AR, et al. Reliability of serum biomarkers of inflammation from repeated measures in healthy individuals. Cancer Epidemiol Biomark Prev. 2012;21:1167\u201370.","DOI":"10.1158\/1055-9965.EPI-12-0110"},{"key":"1968_CR37","doi-asserted-by":"crossref","unstructured":"Gonzalez C, Cava F, Ayllon A, Guevara P, Navajo JA, Gonzalez-Buitrago JM. Biological variation of interleukin-1beta, interleukin-8 and tumor necrosis factor-alpha in serum of healthy individuals. Clin Chem Lab Med. 2001;39:836\u201341.","DOI":"10.1515\/CCLM.2001.139"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01968-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01968-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01968-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T23:10:51Z","timestamp":1727305851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01968-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1968"],"URL":"https:\/\/doi.org\/10.1038\/s41398-022-01968-0","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"assertion":[{"value":"5 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}